Zibotentan
Phase 1Completed 0 watching 0 views this week๐ค Quiet
33
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Liver Cirrhosis
Conditions
Liver Cirrhosis
Trial Timeline
Dec 5, 2024 โ Feb 28, 2025
NCT ID
NCT06715670About Zibotentan
Zibotentan is a phase 1 stage product being developed by AstraZeneca for Liver Cirrhosis. The current trial status is completed. This product is registered under clinical trial identifier NCT06715670. Target conditions include Liver Cirrhosis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06715670 | Phase 1 | Completed |
| NCT05112419 | Phase 1 | Completed |
Competing Products
20 competing products in Liver Cirrhosis